Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 1st Quarter - Termination

AUDENTES THERAPEUTICS

via KING & SPALDING LLP

1st Quarter (Jan 1 - Mar 31) · 2021Posted Apr 19, 2021Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: AUDENTES THERAPEUTICS
Description: Biotechnology company
Location: California · United States of America

Registrant

Firm: KING & SPALDING LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Advocacy related to value-based payments for regenerative medicines
LobbyistsALLISON F KASSIR · mr DAVID JOSEPH FARBER
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

AUDENTES THERAPEUTICS — Lobbying — Receipts Report